Alnylam Pharmaceuticals vs Insmed
ALNY and INSM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and INSM compare
Insmed is the larger company, worth 1.3 times as much as Alnylam Pharmaceuticals ($26.7B against $21.0B).
Insmed grew revenue faster over the last twelve months (240% versus 56.2% for Alnylam Pharmaceuticals).
Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with −39.9% at Insmed.
Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | INSM |
|---|---|---|
| Size and price | ||
| Market cap | $21.0B | $26.7B |
| Share price | $156.50 | $121.86 |
| Change, 1 year | −65.2% | −36.9% |
| Change, 5 years | −17.0% | 321% |
| Beta (5Y) | 0.92 | 0.84 |
| Employees | 2,500 | 1,664 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.1× | – |
| P/S | 4.2× (better) | 17.6× |
| P/B | 5.8× (better) | 36.8× |
| EV/EBITDA | 16.8× | – |
| P/FCF | 26.0× | – |
| FCF yield | 3.8% (better) | −2.3% |
| Fair value | $296.91 | $61.10 |
| Margin of safety | 47.3% (better) | −99.5% |
| Growth | ||
| Revenue growth (TTM) | 56.2% | 240% (better) |
| Revenue growth, 5Y average | 49.8% (better) | 29.8% |
| Net income growth (TTM) | 2137% | – |
| EPS growth (TTM) | 2308% | – |
| Profitability | ||
| Gross margin | 77.4% | 84.4% (better) |
| Operating margin | 19.5% (better) | −37.1% |
| Net margin | 52.8% (better) | −39.9% |
| FCF margin | 16.1% (better) | −41.3% |
| Return on equity | 127% (better) | −72.5% |
| Financial health | ||
| Debt / equity | – | 0.76 |
| Interest coverage | 3.2× (better) | −6.9× |
| Current ratio | 2.48 | 2.86 (better) |
| Altman Z-score | 3.62 | 7.42 (better) |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.7% | 102% |
| Held by insiders | 0.49% | 0.89% |
| Insider net buying, 12 months | −$26.3M (better) | −$133M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.1% | 6.5% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- INSM stock overview
- INSM income statement
- INSM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.